FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study

被引：4

作者：

Giornelli, Gonzalo ^{[1
]}

Gallardo, Dolores ^{[2
]}

Hegg, Roberto ^{[3
]}

Abuin, Gonzalo Gomez ^{[4
]}

La Vega, Maximo De ^{[5
]}

Lim-Law, Maria ^{[6
]}

Caceres, Valeria ^{[7
]}

Trujillo, Lina ^{[8
]}

Pilar Estevez-Diz, Maria del ^{[9
]}

Pacheco, Cristian

Sganga, Leonardo ^{[10
,11
]}

Goncalves, Susana ^{[11
]}

机构：

[1] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina

[2] Hosp Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[3] Hosp Perola Byington, Sao Paulo, Brazil

[4] Hosp Aleman, Dept Oncol, Buenos Aires, DF, Argentina

[5] CEMIC Ctr Educ Med & Invest Clin, Dept Internal Med, Buenos Aires, DF, Argentina

[6] Hosp Santa Fe, Ctr Oncol Panama, Panama City, Panama

[7] Inst Oncol Angel H Roffo, Dept Clin Oncol, Buenos Aires, DF, Argentina

[8] Inst Nacl Cancerol, Clin Ginecol, Bogota, Colombia

[9] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[10] Oncosalud, Lima, Peru

[11] AstraZeneca, Buenos Aires, DF, Argentina

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 13期

关键词：

BRCA; Latin America; mutation testing; ovarian cancer; MAINTENANCE THERAPY; TREATMENT RESPONSE; DOUBLE-BLIND; MUTATIONS; PREVALENCE; BREAST; GENES; CARCINOMA; VARIANTS; WOMEN;

D O I：

10.2217/fon-2020-1152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: FLABRA (NCT02984423) evaluated prevalence of BRCA mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients & methods: Patients with ovarian cancer from six Latin American countries were enrolled. Tumor samples were tested for BRCA mutations. In cases with BRCA mutations (BRCA(mut)), blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan. Results: From 472 patients enrolled, 406 samples yielded conclusive results: 282 were BRCA wild-type (BRCA(wt)), 115 were BRCA(mut) and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic). Conclusion: Tumor testing to identify mutations in BRCA1/2 in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America.

引用

页码：1601 / 1609

页数：9

共 24 条

[1] Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations
Alemar, Barbara
Herzog, Josef
Oliveira Netto, Cristina Brinckmann
Artigalas, Osvaldo
Schwartz, Ida Vanessa D.
Bittar, Camila Matzenbacher
Ashton-Prolla, Patricia
Weitzel, Jeffrey N.
[J]. CANCER GENETICS, 2016, 209 (09) : 417 - 422
[2] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, Kathryn
Fereday, Sian
Meldrum, Cliff
deFazio, Anna
Emmanuel, Catherine
George, Joshy
Dobrovic, Alexander
Birrer, Michael J.
Webb, Penelope M.
Stewart, Colin
Friedlander, Michael
Fox, Stephen
Bowtell, David
Mitchell, Gillian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2654 - 2663
[3] Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review
Andres Ossa, Carlos
Torres, Diana
[J]. ONCOLOGIST, 2016, 21 (07) : 832 - 839
[4] Integrated genomic analyses of ovarian carcinoma
Bell, D.
Berchuck, A.
Birrer, M.
Chien, J.
Cramer, D. W.
Dao, F.
Dhir, R.
DiSaia, P.
Gabra, H.
Glenn, P.
Godwin, A. K.
Gross, J.
Hartmann, L.
Huang, M.
Huntsman, D. G.
Iacocca, M.
Imielinski, M.
Kalloger, S.
Karlan, B. Y.
Levine, D. A.
Mills, G. B.
Morrison, C.
Mutch, D.
Olvera, N.
Orsulic, S.
Park, K.
Petrelli, N.
Rabeno, B.
Rader, J. S.
Sikic, B. I.
Smith-McCune, K.
Sood, A. K.
Bowtell, D.
Penny, R.
Testa, J. R.
Chang, K.
Dinh, H. H.
Drummond, J. A.
Fowler, G.
Gunaratne, P.
Hawes, A. C.
Kovar, C. L.
Lewis, L. R.
Morgan, M. B.
Newsham, I. F.
Santibanez, J.
Reid, J. G.
Trevino, L. R.
Wu, Y. -Q.
Wang, M.
[J]. NATURE, 2011, 474 (7353) : 609 - 615
[5] CALLENS C, 2017, ANN ONCOL, V28, P330
[6] BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population
Cardoso, Florencia C.
Goncalves, Susana
Mele, Pablo G.
Liria, Natalia C.
Sganga, Leonardo
Diaz Perez, Ignacio
Podesta, Ernesto J.
Solano, Angela R.
[J]. HUMAN GENOMICS, 2018, 12
[7] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Coleman, Robert L.
Oza, Amit M.
Lorusso, Domenico
Aghajanian, Carol
Oaknin, Ana
Dean, Andrew
Colombo, Nicoletta
Weberpals, Johanne, I
Clamp, Andrew
Scambia, Giovanni
Leary, Alexandra
Holloway, Robert W.
Amenedo Gancedo, Margarita
Fong, Peter C.
Goh, Jeffrey C.
O'Malley, David M.
Armstrong, Deborah K.
Garcia-Donas, Jesus
Swisher, Elizabeth M.
Floquet, Anne
Konecny, Gottfried E.
McNeish, lain A.
Scott, Clare L.
Cameron, Terri
Maloney, Lara
Isaacson, Jeff
Goble, Sandra
Grace, Caroline
Harding, Thomas C.
Raponi, Mitch
Sun, James
Lin, Kevin K.
Giordano, Heidi
Ledermann, Jonathan A.
[J]. LANCET, 2017, 390 (10106) : 1949 - 1961
[8] Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
Cotrim, Deborah Porto
Goncalves Ribeiro, Adriana Regina
Paixao, Daniele
de Queiroz Soares, Diogo Cordeiro
Jbili, Rima
Pandolfi, Natasha Carvalho
Cezana, Camila
Mauro, Carine de Cassia
Mantoan, Henrique
Bovolim, Graziele
de Brot, Louise
Torrezan, Giovana Tardin
Carraro, Dirce Maria
Baiocchi, Glauco
da Cruz Formiga, Maria Nirvana
da Costa, Alexandre A. B. A.
[J]. BMC CANCER, 2019, 19 (1)
[9] The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective
Dutil, Julie
Golubeva, Volha A.
Pacheco-Torres, Alba L.
Diaz-Zabala, Hector J.
Matta, Jaime L.
Monteiro, Alvaro N.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 441 - 453
[10] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Gonzalez-Martin, A.
Pothuri, B.
Vergote, I.
DePont Christensen, R.
Graybill, W.
Mirza, M. R.
McCormick, C.
Lorusso, D.
Hoskins, P.
Freyer, G.
Baumann, K.
Jardon, K.
Redondo, A.
Moore, R. G.
Vulsteke, C.
O'Cearbhaill, R. E.
Lund, B.
Backes, F.
Barretina-Ginesta, P.
Haggerty, A. F.
Rubio-Perez, M. J.
Shahin, M. S.
Mangili, G.
Bradley, W. H.
Bruchim, I.
Sun, K.
Malinowska, I. A.
Li, Y.
Gupta, D.
Monk, B. J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) : 2391 - 2402

← 1 2 3 →